Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Cash (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Change in Cash for 15 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 218.58% year-over-year to $3.2 million, compared with a TTM value of -$18.4 million through Sep 2025, down 165.8%, and an annual FY2024 reading of $13.4 million, up 227.23% over the prior year.
  • Change in Cash was $3.2 million for Q3 2025 at Fennec Pharmaceuticals, up from -$4.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $37.9 million in Q1 2024 and bottomed at -$13.7 million in Q4 2024.
  • Average Change in Cash over 5 years is -$171625.0, with a median of -$3.4 million recorded in 2022.
  • Peak annual rise in Change in Cash hit 804.22% in 2024, while the deepest fall reached 1673.1% in 2024.
  • Year by year, Change in Cash stood at -$3.6 million in 2021, then tumbled by 66.38% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870000.0 in 2023, then tumbled by 1673.1% to -$13.7 million in 2024, then surged by 123.69% to $3.2 million in 2025.
  • Business Quant data shows Change in Cash for FENC at $3.2 million in Q3 2025, -$4.0 million in Q2 2025, and -$4.0 million in Q1 2025.